Molecular Templates, Inc.

Biogen Idec Ma Inc.

Brian A Elenbaas

Antonio Gualberto

Charles Praray Hart

Matthew B Jarpe

Steven Donald Miklasz

Stephen E Fawell

Lei Shen

Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.

Predictive biomarker for hypoxia-activated prodrug therapy

CYP2W1 levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of a hypoxia-activated achiral phosphoramidate mustards.

This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids.

Growing community of inventors

Melrose, MA, United States of America

Brian A Elenbaas